CSF1R
Macrophage colony-stimulating factor 1 receptor
As of the edition of 20 October 2026, CSF1R (macrophage colony-stimulating factor 1 receptor, UniProt P07333) has 26 drugs tested at it and 29 companies on the list, 11 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P07333
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 26
- Disease areas
- Cancer; Urinary and reproductive; Pregnancy and women's health; Blood and lymph; Lungs and airways; Skin and connective tissue; Digestive system; Hormones
- Registered trials of its drugs
- 494
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 6 |
| Active | 5 |
| Went quiet | 6 |
| Stopped | 7 |
| Status not established | 2 |
| Total | 26 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Pazopanib | Marketed | Phase 4 | none listed |
| Quizartinib | Marketed | Phase 3 | Ends 2030 |
| Vatalanib | Went quiet | Phase 3 | none listed |
| Pexidartinib | Marketed | Phase 4 | Ends 2036 |
| Axatilimab | Marketed | Phase 3 | Ends 2036 |
| Linifanib | Stopped | Phase 3 | none listed |
| Pimicotinib | Marketed | Phase 3 | none listed |
| Cabiralizumab | Stopped | Phase 2 | none listed |
| Vimseltinib | Marketed | Phase 3 | Ends 2044 |
| ENMD-2076 | Went quiet | Phase 2 | none listed |
| Emactuzumab | Active | Phase 3 | none listed |
| Seralutinib | Active | Phase 3 | none listed |
12 of 26 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 11 |
| Route B | 3 |
| Engaged | 12 |
| Undetermined | 3 |
| Total on the list | 29 |
The other 26 companies at CSF1R
In the product29 companies in all; 26 are not named here, and no score is.
See the 29 companies at CSF1R, ranked, with the facts behind eachRequest access. Nothing is shown until you do.